3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Gastrointestinal
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Dexamethasone
33
Lenalidomide
14
pomalidomide
12
daratumumab
12
Bortezomib
12
venetoclax
7
Cyclophosphamide
7
isatuximab
6
Therapeutics
6
trametinib
4
carfilzomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
fludarabine
3
dabrafenib
3
Vemurafenib
3
Rituximab
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Drug Therapy
3
Denosumab
3
Ciprofloxacin
3
Calcium Dobesilate
3
ridaforolimus
2
pembrolizumab
2
molibresib
2
liposomal amphotericin B
2
fludarabine phosphate
2
cobimetinib
2
afuresertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled